Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.
Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.
Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.
Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.
Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.
Despite FDA warnings that patients who stopped treatment of Amgen's Prolia had a high risk of fractures, a consumer watchdog is calling for more.
Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.
As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.
Allergan’s digital booking platform for aesthetic treatments helps consumers find Allergan-branded medical aesthetics but also regular spa services.
United Therapeutics faces allegations of illegally blocking Remodulin generics by teaming with a devicemaker.